Our findings related to augmented HSP90 protein abundance during PD are coherent with previous findings underlining that the HSP90 inhibitor, Geldanamycin (GA), potentially reduces the α-synuclein oligomer and aggregate formation as well as induces α-synuclein clearance [71]. Here, SNCA is linked to Parkinson disease.